William C JR Bertrand
CIK 1291937 · Chief Operating Officer · last filed 2026-06-18
William C JR Bertrand is a Chief Operating Officer who has filed 50 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for ARDX, was dated Jun 18, 2026. Across all open-market trades the lifetime net is +$43.8K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.27M
6
50
$43.8K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARDX | Director | 329,507 | $4.00 | $1.32M | $100.0K | 14 | 2026-06-18 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Chief Operating Officer | 986,352 | $0.06 | $57.1K | -$44.0K | 23 | 2025-08-29 |
| ASND | Chief Operating Officer | 3,731 | $255.41 | $952.9K | -$12.2K | 3 | 2019-01-16 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | General Counsel | — | $0.04 | — | $0 | 1 | 2015-10-21 |
| SALIX PHARMACEUTICALS LTD (SLXP) Delisted | See Remarks | 31,258 | — | — | $0 | 2 | 2015-02-03 |
| MEDI | SVP, General Counsel, Sec | 0 | $33.99 | $0 | $0 | 3 | 2007-06-19 |
Recent Filings
50 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-18 | ARDX | Grant (A) | +38,800 | $0 | EDGAR |
| 2025-08-29 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −207,000 | -$2.1K | EDGAR |
| 2025-08-29 | — | Notice (144) | −34,500 | -$2.1K | EDGAR |
| 2025-06-23 | ARDX | Grant (A) | +60,941 | $0 | EDGAR |
| 2025-02-20 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-01-17 | — | Notice (144) | −5,584 | -$3.2K | EDGAR |
| 2025-01-17 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −5,584 | -$3.2K | EDGAR |
| 2025-01-15 | — | Notice (144) | −9,739 | -$5.7K | EDGAR |
| 2025-01-15 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −19,542 | -$11.4K | EDGAR |
| 2024-06-17 | ARDX | Grant (A) | +11,023 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.